Literature DB >> 18723766

Temporally controlled overexpression of cardiac-specific PI3Kalpha induces enhanced myocardial contractility--a new transgenic model.

Naohiro Yano1, Andy Tseng, Ting C Zhao, Jeffrey Robbins, James F Padbury, Yi-Tang Tseng.   

Abstract

The phosphatidylinositol 3-kinase (PI3K) signaling pathway regulates multiple cellular processes including cell survival/apoptosis and growth. In the cardiac context, PI3Kalpha plays important roles in cardiac growth. We have shown that cardiac PI3K activity is highly regulated during development, with the highest levels found during the fetal-neonatal transition period and the lowest levels in the adult. There is a close relationship between cardiomyocyte proliferation and cardiac PI3K activity. In adult transgenic mice, however, the prolonged constitutive activation of PI3Kalpha in the heart results in hypertrophy. To develop a strategy to allow temporally controlled overexpression of cardiac PI3Kalpha, we engineered a tetracycline (tet) transactivator tet-off controlled transgenic mouse line with a conditional overexpression of a cardiac-specific fusion protein of the SH2 domain of p85 and p110alpha. Cardiac PI3K activity and Akt phosphorylation were significantly increased in adult mice after transgene induction following the removal of doxycycline for 2 wk. The heart weight-to-body weight ratio was not changed, and there were no signs of cardiomyopathy. The overexpression of PI3Kalpha resulted in increased left ventricular (LV) developed pressure and the maximal and minimal positive values of the first derivative of LV pressure, but not heart rate, as assessed in Langendorff hearts. Mice overexpressing PI3Kalpha also had increases in the levels of Ca(2+)-regulating proteins, including the L-type Ca(2+) channels, ryanodine receptors, and sarco(endo)plasmic reticulum Ca(2+)-ATPase 2a. Thus the temporally controlled overexpression of cardiac PI3Kalpha does not induce hypertrophy or cardiomyopathy but results in increased contractility, probably via the increased expression of multiple Ca(2+)-regulating proteins. These distinct phenotypes suggest a fundamental difference between transgenic mice with temporal or prolonged activation of cardiac PI3Kalpha.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723766      PMCID: PMC2593510          DOI: 10.1152/ajpheart.00531.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  23 in total

Review 1.  Phosphoinositide 3-kinase controls early and late events in mammalian cell division.

Authors:  Zaira García; Amit Kumar; Miriam Marqués; Isabel Cortés; Ana C Carrera
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

2.  Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma.

Authors:  U Maier; A Babich; B Nürnberg
Journal:  J Biol Chem       Date:  1999-10-08       Impact factor: 5.157

3.  Ontogeny of phosphoinositide 3-kinase signaling in developing heart: effect of acute beta-adrenergic stimulation.

Authors:  Yi-Tang Tseng; Naohiro Yano; Adam Rojan; Joan P Stabila; Bethany G McGonnigal; Vlad Ianus; Rajan Wadhawan; James F Padbury
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-08       Impact factor: 4.733

4.  Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter.

Authors:  Atsushi Sanbe; James Gulick; Mark C Hanks; Qiangrong Liang; Hanna Osinska; Jeffrey Robbins
Journal:  Circ Res       Date:  2003-03-06       Impact factor: 17.367

5.  Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.

Authors:  T F Franke; D R Kaplan; L C Cantley; A Toker
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

6.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

Authors:  Sohye Kang; Andreas G Bader; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

7.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.

Authors:  Ichiro Shiojima; Kaori Sato; Yasuhiro Izumiya; Stephan Schiekofer; Masahiro Ito; Ronglih Liao; Wilson S Colucci; Kenneth Walsh
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

8.  Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt.

Authors:  Young-Kwon Kim; Song-Jung Kim; Atsuko Yatani; Yanhong Huang; Germana Castelli; Dorothy E Vatner; Jing Liu; Qizhi Zhang; Gissela Diaz; Renata Zieba; Jill Thaisz; Alessandra Drusco; Carlo Croce; Junichi Sadoshima; Gianluigi Condorelli; Stephen F Vatner
Journal:  J Biol Chem       Date:  2003-09-16       Impact factor: 5.157

Review 9.  Targeting altered calcium physiology in the heart: translational approaches to excitation, contraction, and transcription.

Authors:  Tim Seidler; Gerd Hasenfuss; Lars S Maier
Journal:  Physiology (Bethesda)       Date:  2007-10

10.  A novel signaling pathway for beta-adrenergic receptor-mediated activation of phosphoinositide 3-kinase in H9c2 cardiomyocytes.

Authors:  Naohiro Yano; Vlad Ianus; Ting C Zhao; Andy Tseng; James F Padbury; Yi-Tang Tseng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-03-16       Impact factor: 4.733

View more
  19 in total

Review 1.  Specific PI3K isoform modulation in heart failure: lessons from transgenic mice.

Authors:  Alessandra Ghigo; Fulvio Morello; Alessia Perino; Federico Damilano; Emilio Hirsch
Journal:  Curr Heart Fail Rep       Date:  2011-09

2.  Restoration of defective L-type Ca2+ current in cardiac myocytes of type 2 diabetic db/db mice by Akt and PKC-ι.

Authors:  Zhongju Lu; Lisa M Ballou; Ya-Ping Jiang; Ira S Cohen; Richard Z Lin
Journal:  J Cardiovasc Pharmacol       Date:  2011-10       Impact factor: 3.105

3.  Exercise training and PI3Kα-induced electrical remodeling is independent of cellular hypertrophy and Akt signaling.

Authors:  Kai-Chien Yang; Yi-Tang Tseng; Jeanne M Nerbonne
Journal:  J Mol Cell Cardiol       Date:  2012-07-21       Impact factor: 5.000

Review 4.  Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels.

Authors:  Lisa M Ballou; Richard Z Lin; Ira S Cohen
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

5.  Excitation-contraction coupling in ventricular myocytes is enhanced by paracrine signaling from mesenchymal stem cells.

Authors:  J DeSantiago; D J Bare; I Semenov; R D Minshall; D L Geenen; B M Wolska; K Banach
Journal:  J Mol Cell Cardiol       Date:  2012-03-23       Impact factor: 5.000

6.  Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?

Authors:  Xiang Wang; Ana-Maria Bosonea; Jeffrey Odenbach; Carlos Fernandez-Patron
Journal:  Curr Hypertens Rev       Date:  2012-08-01

Review 7.  Signaling to cardiac hypertrophy: insights from human and mouse RASopathies.

Authors:  Valentina Sala; Simona Gallo; Christian Leo; Stefano Gatti; Bruce D Gelb; Tiziana Crepaldi
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

8.  Role of phosphoinositide 3-kinase {alpha}, protein kinase C, and L-type Ca2+ channels in mediating the complex actions of angiotensin II on mouse cardiac contractility.

Authors:  Wenbin Liang; Gavin Y Oudit; Mikin M Patel; Ajay M Shah; James R Woodgett; Robert G Tsushima; Michael E Ward; Peter H Backx
Journal:  Hypertension       Date:  2010-08-09       Impact factor: 10.190

9.  Phosphoinositide-3-kinase/akt - dependent signaling is required for maintenance of [Ca(2+)](i), I(Ca), and Ca(2+) transients in HL-1 cardiomyocytes.

Authors:  Bridget M Graves; Thomas Simerly; Chuanfu Li; David L Williams; Robert Wondergem
Journal:  J Biomed Sci       Date:  2012-06-20       Impact factor: 8.410

Review 10.  Role of PI3K/Akt signaling pathway in cardiac fibrosis.

Authors:  Wuming Qin; Linghui Cao; Isaac Yaw Massey
Journal:  Mol Cell Biochem       Date:  2021-07-10       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.